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Preparation of high quality allergen extracts is essential for the diagnosis and im-
munotherapy of allergic disorders. Standardization of allergen extracts concerns 
determination of the allergen unit, development of reference material and mea-
surement of the overall IgE binding capacity of an allergen extract. Recently, 
quantification of individual allergens has been the main focus of allergen standard-
ization because the allergenicity of most allergen extracts is known to be mainly 
dependent on the content of a small number of allergen molecules. Therefore, 
characterization of major allergens will facilitate the standardization of allergens. 
In this article, we review the current state of allergen standardization. In addition, 
we briefly summarize the components of allergen extracts that should be under 
control for the optimization of allergen standardization, since its adjuvant-like ac-
tivities could play an important role in allergic reactions even though the molecule 
itself does not bind to the IgE antibodies from subjects.
Key Words:   Allergen extracts, natural adjuvant, polymorphism, standardization
INTRODUCTION
Extracts from various allergenic sources have been used for the diagnosis and aller-
gen-specific immunotherapy of type I hypersensitivity since 1911.1,2 However, the 
quality of commercial allergen extract has been repeatedly reported to be variable.3-6 
Biological standardization, which mainly determines overall IgE-binding poten-
cy, is generally carried out to assess the quality of allergen extracts. The Center for 
Biologics Evaluation and Research (CBER) in the US Food and Drug Administra-
tion (FDA) maintains 19 US reference standards for potency; six Hymenoptera 
venoms, two house dust mites, two cat dander extracts, one short ragweed pollen, 
and eight grass pollens.7 More specifically, grasses and mite allergen extracts are 
standardized on the basis of overall allergens with pooled serum by ELISA. Aller-
gen potency of cat and ragweed allergen extracts is evaluated by determination of 
specific allergen with a sheep antibody by immunodiffusion. Allergenicity of Hy-
menoptera venoms are mainly assessed by total protein content and enzymatic ac-
tivities. All manufacturers in the US are required to demonstrate batch-to-batch 
consistency and compliance with the standard. However, in-house reference (IHR) 
preparations from the companies are utilized for standardization in European 
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recombinant allergens.10
The extraction procedure should reflect the physiological 
conditions of the airway. Generally, raw source materials 
are freeze-dried, and proteins are extracted using buffers re-
sembling the physiological conditions of human airway. 
Extracted proteins are dialyzed to eliminate chemicals and 
hapten molecules. Effort should be made to suppress pro-
teolytic degradation and contamination and the growth of 
microorganisms.
ALLERGEN UNIT
  
Commonly used allergen units are summarized in Table 1. 
The Noon unit and the protein nitrogen unit (PNU) were 
widely used for allergen products. A Noon unit denotes the 
quantity of water-soluble protein extractable from 1 μg of 
pollen.1 An allergen extract prepared from one gram of pol-
len in 10 mL of extraction buffer contains 100,000 Noon 
units per mL. Pollen derived from different sources is as-
sumed to have the same allergenic activity. The weight per 
volume system is still widely used. PNU was introduced 
because most allergens were found to be proteins. PNU cor-
responds to 0.01 μg phosphotungstic acid-precipitable nitro-
gen, which is approximately 0.06 μg of protein.11 Recently, 
countries.8 Therefore, each manufacturer uses a different 
unit for labelling the allergenic activity, making it difficult 
to interchange products between different companies. 
SELECTION OF ALLERGEN SOURCE 
MATERIALS
Selection of raw materials is the first step for the prepara-
tion of an allergen extract. The quality of an allergen extract 
directly reflects the identity and purity of the allergenic 
source materials. Samples should be collected by qualified 
personnel. The content of all relevant allergens should be 
verified by appropriate methods. It may be necessary to cul-
ture or cultivate plants and animals of the allergen source in 
order to control the possible contamination of microbes, 
which can produce natural adjuvant-like susbstances in the 
allergen extract. Interestingly, it has been reported that aller-
gen extracts prepared even from the same species of house 
dust mite, Dermatophagoides pteronyssinus, obtained from 
manufacturers in geographically distinct regions such as 
Sweden, Chile, and Australia, were found to exhibit re-
markably different IgE reactivity.9 In contrast, the popula-
tions of mite-allergic patients in different geographic regions 
also showed different IgE reactivity to purified natural and 
Table 1. Allergen Units Currently Used by Individual Allergen Manufacturers
Manufacturer Allergen Unit Standardization
Alk-Albero
Biologic unit (BU)
Skin prick test
Histamine equivalent unit (HEP)
Standard treatment unit  (STU)
Standardized quality units tablet (SQ-U)
Allerbio
Index of reactivity (IR)
Skin prick test
Biologische Einheiten (BE)
Allergopharma
Standard biological unit (SBE)
Skin prick testTherapeutic unit (TU)
Sublinguale Einheiten (SE)
Allergy therapeutics
Therapeutic unit (TU)
Skin prick testStandard oral unit (SOU)
Diagnostic unit (DU)
ARTU Biologicals Biologische Einheiten (BE) Skin prick test
HAL Allergy Bioequivalent allergen unit (BAU) Intradermal skin test
HolisterStier Bioequivalent allergen unit (BAU) Intradermal skin test
Immunotek Therapeutic unit (TU) Skin prick test
IPI-ASAC
Unidades biologicas equivalentes 
  (UBE: equivalent biological unit)
Skin prick test
Laboratorios LETI Histamine equivalent prick leti (HEPL) Skin prick test
Stallergenes
Index of reactivity (IR)
Skin prick test
Index of concentration (IC)
Optimization of Allergen Standardization
Yonsei Med J   http://www.eymj.org   Volume 52   Number 3   May 2011 395
able from the National Institute of Biological Science and 
Control (NIBSC), London. However, these standard mate-
rials have not been widely utilized for the standardization 
of commercial products because they were determined 
based on IgE potency tests, which use various serum pools 
and cannot distinguish the ratios of major allergens that are 
not identical between companies.
MAJOR ALLERGEN CONTENT
  
An alternative approach is necessary to overcome these 
problems caused by using allergen extracts containing a 
mixture of antigens and toxic substances such as endotoxin, 
enterotoxin, and/or proteases, which may play a role as an 
allergic adjuvant. The use of combinations of optimized 
concentrations of purified allergens, recombinant or native 
proteins, seems to be advantageous.18,19 Measurement of the 
concentration of individual major allergens is reported to 
correlate with the biological potency and IgE reactivity of 
allergen extracts.20,21 Furthermore, clinical trials using cock-
tails of recombinant allergens have demonstrated clinical 
efficacy, supporting the importance of major allergen con-
tent for immunotherapy.22,23 It also facilitates direct compar-
ison between allergen products.24
The CREATE project (Development of Certified Refer-
ence Materials for Allergenic Products and Validation of 
Methods for their Quantification) was initiated by the Euro-
pean Commission from nine European Union member 
states in order to evaluate the potential of purified natural or 
recombinant allergens as certified reference materials, and 
to validate available two-site ELISAs for the measurement 
of major allergens.25 So far, two reference materials (rBet v 
1 and rPhl p 5a) and relevant ELISA assays are now being 
validated for future establishment as international referenc-
es under the guidance of the European Directorate for the 
Quality of Medicine (EDQM) after extensive biological 
and biochemical investigation. Currently, these two refer-
ence materials (rBet v 1 and rPhl p 5a) are under further 
validation by BSP090 project. The CREATE project leads 
us to conclude that standardization with major allergens is 
possible, even though recombinant allergens and monoclo-
nal antibody-based immunoassays are not always ideal. 
Still, standardization based on major allergen content seems 
to be reasonable for determining the optimal dose of aller-
gen vaccine, inducing a clinically relevant effect in the ma-
jority of subjects without unacceptable side effects. It is 
histamine equivalent in prick testing (HEP), biologic unit 
(BU), and bioequivalent allergen unit (BAU) have come to 
be widely used on standardized products. Ten HEP is equiva-
lent to the allergen concentration, which elicits the same 
wheal size on a skin prick test as 10 mg/mL of histamine di-
hydrochloride.12 BU represents 1/1,000 of HEP since 10,000 
BU/mL is equivalent to 10 HEP. However, the detailed meth-
od determining the unit differs between manufacturers even 
though most of the companies utilize the skin prick test.4 
BAU is based on intradermal skin tests.13 The 3-fold dilution 
(0.05 mL) is calculated to induce a sum of erythema of 50 
mm (D50). The allergen extract with a D50 of 14th dilution 
is arbitrarily assigned 100,000 BAU/mL [BAU/mL= 
100,000×3(D50-14)]. However, these approaches can’t be ap-
plied to the chemically modified allergens (allergoids) or hy-
poallergenic allergens (which are currently not commercially 
available).14
For in vitro standardization, competitive IgE-binding in-
hibition test (e.g., ELISA or RAST) has proven to be reliable 
and is most commonly applied for measurement of total al-
lergenic activity.15 The relative potency may be calculated by 
comparing activity with the potency of reference allergen 
extracts. Various biochemical and immunological methods 
such as SDS-PAGE, immunoelectrophoresis, circular di-
chroism spectrum analysis, immunoblotting, mass-spectro-
metric analysis, dot blot analysis, and proteomic approach-
es, etc. could be performed to check and control the consistent 
composition and activity of allergen product. However, IgE-
reactivity does not reflect ability to cause allergic symp-
toms. The basophil activation test utilizes the same mecha-
nism as a skin test and is expected to more closely reflect 
the biological activity of allergens, although it has not been 
widely utilized until now.16,17
ALLERGEN STANDARD
  
Production of allergen standard is essential for the standard-
ization of allergen extracts. In fact, international reference 
standards were produced under the auspices of WHO ac-
cording to the guidelines established by the Allergen Stan-
dardization Subcommittee under the International Union of 
Immuunological Societies (IUIS) for short ragweed (Am-
broisia artemisiifolia), timothy grass (Phleum pratense), 
birch (Betula verrucosa) pollen, house dust mite (Derma-
tophagoides pteronyssinus), and dog (Canis familiaris) be-
tween 1984 and 1989. These allergen extracts are obtain-
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environment or allergen extract by using immunoassay kits.37
NATURAL ADJUVANT  
IN ALLERGENS EXTRACT
Some component of allergen extract could activate innate 
and/or adaptive immunity. In particular, house dust mites 
have been known to contain many substances that could in-
duce innate immunity, subsequently affecting the develop-
ment of allergic responses.38 Some proteins in allergen ex-
tract, whether they are allergens themselves or not, can 
activate the various human cell and induce inflammatory 
responses.39
Some common contaminants from the indoor environ-
ment can play a role in the development of allergic disorders 
through their adjuvant-like activity. Several lines of evidence 
have been described on the relationship between pathogen-
associated molecular patterns (PAMPs).40 Endotoxin has 
been implicated as an important modulator of allergic re-
sponses.41,42 Natural adjuvant derived from various microbes 
may affect allergy diagnosis and immunotherapy as well as 
pathogenesis of allergic disorders. Interestingly, the major 
house dust mite allergen Der p 2, homologous to MD-2, 
was shown to reconstitute lipopolysaccharide-induced TLR4 
signalling in MD-2-deficient mice.43
Endotoxin, one of the well-described cell wall compo-
nents of gram-negative bacteria, is known to induce inflam-
matory responses in human cells, subsequently affecting al-
lergic diseases.44 Several lines of evidence have shown that 
sequence variation of TLR-2 and -4 genes are associated 
with the development of allergic disorders.45 In a normal in-
door environment, 300-18,000 ng/g dust of endotoxin was 
detected.44 This concentration implies that a significant 
amount of endotoxin is breathed in and can have influence 
on immune reactions. Exposure to the high level of endo-
toxin is thought to protect against the allergy. However, low 
level of endotoxin is believed to worsen allergic symptoms.
β-glucan, a component of fungal cell walls, is another 
common component of the indoor environment. It is also 
known to modulate allergic responses, influencing both the 
Th1 and Th2 responses.46,47 Notably, 0.4-41.8 ng/mL of 
β-glucan was detected in standardized allergen extracts.48
Various enzyme activities have been detected from the 
allergen extracts and house dust.49,50 Mite group 1, 3, 6, and 
9 allergens are cysteine protease, trypsin-like serine prote-
ase, chymotrypsin-like serine protease, and collagenolytic 
generally thought that 5-20 μg of major allergen (50-250 
μg/yr) for house dust mite, cat, ragweed, and Hymenoptera 
venom are optimal for subcutaneous allergen specific im-
munotherapy. Much higher concentrations are needed for 
sublingual immunotherapy.
SEQUENCE POLYMORPHISMS  
OF ALLERGENS
A mixture of similar molecules with some variation in the 
amino acid sequences, isoallergens or variants often consti-
tutes allergenic proteins.26 This phenomenon, often called 
polymorphism, may be caused by the presence of several 
gene alleles or families. Sequence diversity of major aller-
gens is one of the important factors affecting complete al-
lergen characterization and standardization.21,27 RNA edit-
ing as well as multiple genes were found to produce sequence 
variations, which may influence its allergenicity in case of 
cockroach allergen, Bla g 4.28 Importantly, mite group 2 al-
lergens and birch pollen allergen Bet v 1 showed sequence 
diversity, which could influence IgE-binding reactivity, T 
cell response, and cytokine production from various im-
mune cells.29-32 Extraction procedure and storage can also 
influence allergen contents. Different isoforms could be in-
cluded in different batches of allergen extract. IgE or IgG 
recognition could be affected even by a single amino acid 
substitution on the surface of the allergens.33
Sequence polymorphism also influences reactivity to 
monoclonal antibodies. Commonly used immunoassay kits 
to quantify major allergens in Korea could underestimate the 
quantity of dominant isoforms in Korea.34 In case of Der f 2, 
amino acid sequence variations were described from Korean 
isolates of house dust mite.35 Differences in the capture anti-
body (monoclonal or polyclonal), storage buffer, or micro-
plates showed up to 2-fold differences in two-site ELISA. 
Furthermore, distinct combinations of materials or incuba-
tions from different steps also could produce up to 5-fold dif-
ferences in Can f 1 and egg white analyses.36 Epidemiologi-
cal studies using immunoassay kits are also believed to 
underestimate the allergen content in dust samples. It is nec-
essary to investigate the sequence polymorphism of major al-
lergens that are thought to play important roles in the sensiti-
zation of Korean allergic patients. Studies of the sequence 
polymorphism and identification of major isoforms in each 
country/geographical region are thought to be necessary for 
more accurate determination of allergen content from a given 
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vate chitinases and chitinase-like protein in humans and 
play a role in the pathogenesis of Th2 inflammation.72,73 In-
terestingly, mite allergen Der f 15 and 18 show significant 
homology to chitinases. It would be interesting to explore 
the role of chitinases in the pathogenesis of allergic diseases 
and to examine the chitin content and chitinase activity in 
allergen extracts.
Superantigen, endotoxin B from Staphylococcus in skin, 
is also known to be associated with the development of 
atopic dermatitis by activating T cells.74
DNA fragments derived from microorganisms may have 
various effects on the pathogenesis of allergic disorders. 
Herpes simplex is known to induce production of TNF-α 
by activation of TLR-9.75 DNA fragments may contain the 
CpG motif, which could be protective against allergy.76 
Bacterial DNA are detectable even from house dust mite 
cultures for allergen extract preparation,77 indicating that 
DNA fragments are included in the extracts.
It is noteworthy that many adjuvant-like activities are de-
rived from a microbial component. It is known that com-
mensals in intestine and skin can influence allergic disor-
ders.78 Recently, it has been reported that there are a large 
number of microbiota that can affect allergic diseases.79 Vi-
ral infection can also exacerbate the symptoms via TLR-3, 
-7, -8, -9 activation.80 Concomitant infectious diseases and 
hygiene are important not only for the development of al-
lergic disorders and exacerbation of the symptoms, but also 
for diagnosis and allergy immunotherapy. Currently, it is 
thought to be almost impossible to remove all those elements 
that may play adjuvant-like roles. Therefore, it should be em-
phasized that every effort must be made to minimize possi-
serine protease, respectively.51 Proteins with cysteine or ser-
ine protease activity are well known to induce Th2 immune 
response. Protease allergens can cleave CD23 (low affinity 
IgE receptor) of activated B cells52 and CD25 (IL-2 recep-
tor) of T cells.53 Tight junctions in the lung epithelium could 
be degraded and cause various cells to release inflammato-
ry cytokines.54,55 Degraded epithelium is vulnerable even to 
bystander allergens.56,57 Protease allergens also can cleave 
several component of the complement system, generating 
active anaphylatoxins, C3a, C4a, and C5a.58-60 Furthermore, 
protease-activated receptor 2 is activated and induces proin-
flammatory responses.61,62 Human basophils are known to 
be directly activated by cysteine protease (Der p 1 and Der 
f 1) and to release cytokines, which can induce allergic in-
flammation.63 Some serine protease inhibitors and defects 
of the protease gene are known to be associated with aller-
gic conditions.54 Interestingly, cystatin A, a cysteine prote-
ase inhibitor in secreted sweat, has been shown to eliminate 
the activity of mite group 1 allergens.64 It is also conceiv-
able that some proteases originating from symbionts or par-
asites of allergen sources (house dust mite or cockroach) 
can influence allergic inflammation.65-68 In fact, various mi-
croorganisms, which may secrete or excrete proteases, have 
been isolated from the cockroach hindgut.69  
Flagellin, a principal constituent of bacterial flagellum, is 
one element that may elicit an inflammatory response.70,71 
However, much remains to be investigated. 
Chitin, a major component of the exoskeletons of arthro-
pods, fungal walls and the microfilarial sheath of parasites, 
is the second most abundant polysaccharide in nature. Inha-
lation or infection of chitin-containing pathogen could acti-
Fig. 1. (A) A Japanese hop, an annual climbing vine with 5-lobed leaves and covered with hooked hairs. The pollen of the Japanese hop is 
an important cause of seasonal rhinitis in Asia in August and September. (B) An adult male Chironomus kiiensis, a dominant species of 
non-biting midge in Korea. The emergence of a large number of non-biting midges often causes a nuisance as well as allergies.
A B
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care Technology R&D Project, Ministry for Health, Wel-
fare & Family Affairs, Republic of Korea (A092076).
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ble contamination and suppress microbial growth. It is de-
sirable to check the activity and content of substances that 
may play adjuvant-like roles.
ALLERGEN STANDARDIZATION  
IN KOREA
The allergen extracts produced at the Research Center for the 
Standardization of Allergic Diseases, Department of Internal 
Medicine and Institute of Allergy, Yonsei University College 
of Medicine, Seoul, Korea, exhibit good allergen potency, in 
terms of in vitro (ELISA inhibition) and in vivo (intradermal 
skin test) tests, when compared with commercially available 
extracts, even though immunosassays detected low levels of 
major allergens. Comparisons were performed between en-
dotoxin levels of house dust mite extracts both commercially 
available and produced in our laboratory. The endotoxin lev-
el was determined to be comparable with commercial prod-
ucts even without the addition of phenol (unpublished data).
It is urgently necessary to develop standard references and 
immnoassays for the detection of major allergens, such as 
Japanese hop (Humulus japonicus) (Fig. 1A),81 spider mites 
(Tetranychus urticae and Panonychus citri),82 non-biting 
midge (Chironomus spp) (Fig. 1B),83 Pharaoh ant (Mono-
morium pharaonis),84 and Asian needle ant (Pachydonyla 
chinensis),85 which are frequent causes of allergic illness in 
Korea.
CONCLUDING REMARKS
  
The recent research trend for allergen standardization has 
changed from IgE potency test to characterization of major 
allergens and assays for the quantification of major allergen 
concentrations. Still, measurement of biological potency of 
extracts remains the basis of allergen standardization. Fur-
ther study is required to characterize the major allergens 
that are thought to be important in Korea. Studies on the 
correlation between major allergen concentrations and the 
potency of allergen extracts will facilitate the development 
of advanced allergen-specific immunotherapeutics.
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